New data bolsters Prescient Therapeutics’ focus on next generation CAR-T cell therapy for cancers
New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use...
New data published in the science journal Nature has supported clinical stage oncology company Prescient Therapeutics’ (ASX: PTX) use...
Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of...
A new longitudinal study of cancer patients treated with a revolutionary type of cell therapy...
Cancer is one of the significant causes of death worldwide. As per the World Health...
Biopharmaceutical company Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer has released its...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Kalkine Media...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the December quarter with a...
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR...
To fight the menace of cancer, there have been categorical and highly efficacious progress in...
A clinical-stage oncology company, Prescient Therapeutics (ASX:PTX) has further strengthened its Scientific Advisory Board (SAB) with the...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.